In prostate cancer cell lines, the TP53 414delCmutation was corrected to the wild-type TP53 genotypeby using the CRISPR/Cas9 system, thereby promoting apoptosis and preventingtumor proliferation. This evidence concerns the gene TP53 and prostate cancer.